ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

[1]  D. Raghavan,et al.  Principles of Chemotherapy for Genitourinary Cancer , 2015 .

[2]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Muto,et al.  Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Messing,et al.  DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM‐BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? , 2011, BJU international.

[5]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Ramsey,et al.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.

[7]  E. Messing,et al.  Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology , 2011 .

[8]  Y. Lotan,et al.  Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. , 2011, The Journal of urology.

[9]  E. Messing,et al.  Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) , 2010, BJU international.

[10]  E. Ward,et al.  Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. , 2011, The Journal of urology.

[11]  S. Boorjian,et al.  Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. , 2011, Urology.

[12]  M. Eliasziw,et al.  Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[13]  R. Millikan,et al.  Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder , 2010 .

[14]  V. Guillem,et al.  Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Sonpavde,et al.  Neoadjuvant systemic therapy for urological malignancies , 2009, BJU international.

[16]  David C. Smith,et al.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). , 2009, The Journal of urology.

[17]  H. Grossman,et al.  Commentary on A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience , 2009 .

[18]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[19]  B. Bochner,et al.  Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. , 2009, European urology.

[20]  M. Milowsky,et al.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. , 2009, European urology.

[21]  G. Muto,et al.  Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial , 2008 .

[22]  Y. Lotan,et al.  A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome , 2007, BJU international.

[23]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[24]  R. Millikan,et al.  Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. , 2007, Urology.

[25]  C. Vale.  Adjuvant chemotherapy for invasive bladder cancer (individual patient data). , 2006, The Cochrane database of systematic reviews.

[26]  M. Gallucci,et al.  Adjuvant chemotherapy in muscle‐invasive bladder carcinoma , 2006, Cancer.

[27]  P. Albers,et al.  Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[29]  H. Grossman,et al.  Surgical factors influence bladder cancer outcomes: a cooperative group report. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[31]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[32]  N. James,et al.  The systemic treatment of advanced and metastatic bladder cancer. , 2003, The Lancet. Oncology.

[33]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[34]  I. Tannock,et al.  The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. , 2002, The Lancet. Oncology.

[35]  M. Droller.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. , 2002, The Journal of urology.

[36]  L. Holmberg,et al.  Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer - Nordic Cystectomy Trial 2 , 2002, Scandinavian journal of urology and nephrology.

[37]  K. Kihara,et al.  [Neoadjuvant chemotherapy for invasive bladder cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[39]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Herr,et al.  Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. , 2001, The Journal of urology.

[41]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Sylvester,et al.  The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Thüroff,et al.  Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis , 2000, BJU international.

[44]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[45]  M. Droller.  Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial , 1999, The Lancet.

[46]  B. Donnelly,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.

[47]  S. Lerner.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. , 1999, Lancet.

[48]  M. Ghoneim,et al.  Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. , 1997, The Journal of urology.

[49]  R. Wahlqvist,et al.  Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 , 1996 .

[50]  R. Wahlqvist,et al.  Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. , 1996, The Journal of urology.

[51]  H. Shiina,et al.  Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response. , 1995, British journal of urology.

[52]  J. Portillo,et al.  Original Articles: Bladder Cancer , 1995 .

[53]  H. Scher,et al.  Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Stöckle,et al.  Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. , 1995, The Journal of urology.

[55]  J. Portillo,et al.  Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. , 1995, The Journal of urology.

[56]  J. Rassweiler.  [Neoadjuvant chemotherapy of invasive bladder cancer]. , 1994, Der Urologe. Ausg. A.

[57]  M. Stöckle,et al.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. , 1992, The Journal of urology.

[58]  N. Vogelzang,et al.  The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. , 1992, The Journal of urology.

[59]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.

[60]  H. Scher,et al.  Neoadjuvant chemotherapy for invasive bladder cancer: future directions. , 1990, Seminars in oncology.

[61]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[62]  D. Jacqmin,et al.  EORTC Group Study 30851: a phase II study of neoadjuvant chemotherapy in patients with invasive bladder cancer. , 1990, Progress in clinical and biological research.

[63]  O. Dalesio,et al.  Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response. , 1989, Progress in clinical and biological research.

[64]  R. Babaian,et al.  Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  V. Reuter,et al.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. , 1988, The Journal of urology.